cell microarray technology screen (Charles River Laboratories)
86
Structured Review
Charles River Laboratories
cell microarray technology screen
Cell Microarray Technology Screen, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+microarray+technology+screen/cell+microarray+screen+technology/pm41742895-65-13-17
Average 86 stars, based on 1 article reviews
Cell Microarray Technology Screen, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+microarray+technology+screen/cell+microarray+screen+technology/pm41742895-65-13-17
Average 86 stars, based on 1 article reviews
cell microarray technology screen - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
Binding Assay:Article Title: Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma. Article Snippet: .. Each binding arm of JNJ-80948543 was evaluated for binding specificity in the Retrogenix® Article Title: Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma. Article Snippet: .. The individual CD79b, CD20 and CD3 molecules were screened for binding specificity using the Retrogenix® Article Title: Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models. Article Snippet: For all in vivo studies, female NSG (The Jackson 8 Laboratory) or female NCG (Charles River Laboratories) mice were used when they were 9 approximately 5 to 8 weeks of age and weighed approximately 20 g. 10 .. The binding specificity of the individual BCMA and GPRC5D antibodies were assessed using 12 the Retrogenix Article Title: Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models Article Snippet: For all in vivo studies, female nonobese diabetic (NOD) severe combined immunodeficiency (scid) gamma (NSG; The Jackson Laboratory) mice aged ∼5 to 8 weeks and weighing ∼20 g were used. .. The binding specificity of the individual BCMA and GPRC5D antibodies were assessed using the Retrogenix Microarray:Article Title: Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma. Article Snippet: .. Each binding arm of JNJ-80948543 was evaluated for binding specificity in the Retrogenix® Article Title: Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma. Article Snippet: .. The individual CD79b, CD20 and CD3 molecules were screened for binding specificity using the Retrogenix® Article Title: Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models. Article Snippet: For all in vivo studies, female NSG (The Jackson 8 Laboratory) or female NCG (Charles River Laboratories) mice were used when they were 9 approximately 5 to 8 weeks of age and weighed approximately 20 g. 10 .. The binding specificity of the individual BCMA and GPRC5D antibodies were assessed using 12 the Retrogenix Article Title: Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models Article Snippet: For all in vivo studies, female nonobese diabetic (NOD) severe combined immunodeficiency (scid) gamma (NSG; The Jackson Laboratory) mice aged ∼5 to 8 weeks and weighing ∼20 g were used. .. The binding specificity of the individual BCMA and GPRC5D antibodies were assessed using the Retrogenix |